GlaucomaNCT07769463
Impact of Meditation on Reducing Stress in Glaucoma Patients: An Electronic Feasibility Study
A study of Glaucoma, run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's.
Trial summary
Glaucoma is a chronic disease that causes loss of vision and potentially blindness as a result of optic nerve damage, often due to increased intraocular pressure. Glaucoma is currently the leading cause of irreversible blindness worldwide.1 In 2020, 4.1 million and 3.6 million adults over the age of 50 suffered from… Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Glaucoma
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 158 participants
- Where
- No sites listed yet
- Study dates
- 1 Nov 2026to 1 Dec 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- Diagnosed with glaucoma or suspected to have glaucoma.
- Aged 65 and above.
- Able to provide valid informed consent to participate in the research study.
- Able to read and understand English.
- No significant self-reported or physician-diagnosed mental health disorder.
- Independent access to a computer to participate in virtual sessions.
- Able to sit comfortably for 30 minutes without any major pain or discomfort, can hear well enough to follow verbal instructions when the eyes are closed, and be in good general physical health.
- Willing to practice meditation at home for ~15 minutes per day.
Who cannot join
- Inability to provide valid informed consent.
- Significant communication barriers or lack of English proficiency that prevents participants from completing the questionnaires.
- Self-reported substance abuse or dependence within the past 3 months.
- Having acutely unstable medical illnesses, including delirium or acute cerebrovascular or cardiovascular events within the last 6 months.
- Having irreversible vision loss that prevents one from completing the questionnaires.
- Participation in a study involving similar techniques.
- Established meditation practice, defined as engaging in any formal meditation (e.g., mindfulness, mantra, breath-focused) more than twice per week within the past 3 months.
About this study
Glaucoma is a chronic disease that causes loss of vision and potentially blindness as a result of optic nerve damage, often due to increased intraocular pressure. Glaucoma is currently the leading cause of irreversible blindness worldwide.1 In 2020, 4.1 million and 3.6 million adults over the age of 50 suffered from mild to severe glaucoma-induced visual impairment and blindness, respectively.1 However, these figures are likely underestimated since glaucoma can remain asymptomatic until later stages in disease progression.2 The relaxation response evoked by mind-body interventions, such as breathing exercises and meditation, is known to reduce stress and improve quality of life (QOL). In a recent study, mindfulness-based meditation was found to reduce intraocular pressure and improve QOL in patients with glaucoma.3 A feasibility study will be conducted using a mixed-method design to assess the feasibility of the online delivery of meditation for potentially enhancing the QOL and reducing stress in glaucoma patients. Upon recruitment, participants will undergo blocked randomization to either the intervention arm or usual care arm. Participants in each arm will complete online questionnaires at baseline and weeks 1, 3, 6, and 12 to collect data on health-related quality of life (HRQOL), perceived stress, and behaviour using REDCap. REDCap is an online data collection and survey tool hosted by the Office of Research Services of Lawson Research Institute. Our study can help to assess the feasibility of conducting a study on breathing exercises followed by meditation to assess its effects in a sample of patients with glaucoma.
- Conditions
- Glaucoma
- Being tested
- Meditation + Usual Care
- Medical subject headings
- Glaucoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Meditation + Usual CareOther
Meditation is a guided technique that helps to reduce stress, therefore inducing physiological and mental relaxation whilst the eyes are shut.
| Study group | Role | What they receive |
|---|---|---|
| Meditation + Usual Care | Other | Not described Receives: Other: Meditation + Usual Care |
| Usual Care | No intervention | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of Quality of Life as measured by GQOL- 15 in Glaucoma Patients
HRQoL will be assessed using Glaucoma Quality of Life-15 (GQL-15). GQL-15 is a disease-specific, validated, self-administered questionnaire designed to measure HRQoL in patients with glaucoma. The questionnaire comprises of 15 items on daily functioning across 5 factors: central and near vision (2 items), peripheral vision (6 items), glare and dark adaptation (6 items), and outdoor mobility (1 item). Patients rate these questions on a 5-point Likert scale of difficulty ranging from "1 = no difficulty" to "5 = severe difficulty".
Measured: Data will be collected at baseline and post-intervention at Week 1, 3, 6, and 12.
Secondary outcomes (2)
Incidence of Stress as Measured by PSS-10 in Glaucoma Patients
The Perceived Stress Scale (PSS-10) is a 10-item questionnaire widely used to measure the perception of stress. It is a measure of the degree to which situations in one's life are appraised as stressful. Items were designed to tap how unpredictable, uncontrollable, and overloaded respondents find their lives. The scale also includes several direct queries about current levels of experienced stress. Individual scores on the PSS can range from 0 to 40 with higher scores indicating higher perceived stress. Scores ranging from 0-13 would be considered low stress; scores ranging from 14-26 would be considered moderate stress; and scores ranging from 27-40 would be considered high perceived stress.
Measured: Data will be collected at baseline and post-intervention at Week 1, 3, 6, and 12.
Incidence of Behavior as measured by Consideration of Future Consequences - 14 (CFC-14) in Glaucoma Patients
In previous research, consideration of future consequences (CFC) has been recognized as a critical factor influencing individuals' engagement in health-promoting behaviors. Strathman et al. initially developed a 12-item unidimensional Consideration of Future Consequences (CFC) scale to measure individual differences in temporal orientation. This scale assesses the degree to which individuals consider the potential impact of their current behavior on immediate or distant outcomes.38 Low CFC scores indicate that individuals are more inclined to pursue immediate rewards, whereas high scores are observed among individuals who prioritize future advantages and sacrifice immediate gratification.
Measured: Data will be collected at baseline and post-intervention at Week 1, 3, 6, and 12.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Aug 2026
- Study start1 Nov 2026 (estimated)
- Primary completion1 Nov 2028 (estimated)
- Study completion1 Dec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for GlaucomaStudies of the same condition, open and under way.
- More trials run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Care provider, Investigator, Outcomes assessor
- Enrolment
- 158 participants (estimated)
Sponsor and investigators
- Lead sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07769463
- Sponsor's protocol ID
- 13956
- Other IDs
- R-17-463
- Status last verified
- Aug 2026
- First submitted
- 14 Aug 2026
- Last updated
- 18 Aug 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Impact of Meditation on Reducing Stress in Glaucoma Patients: An Electronic Feasibility Study
- ClinicalTrials.gov ID
- NCT07769463
- Acronym / sponsor ID
- 13956
- Conditions
- Glaucoma
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 158 participants (estimated)
- Lead sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sUniversity, hospital or other
- Study start
- 1 Nov 2026 (estimated)
- Primary completion
- 1 Nov 2028 (estimated)
- Study completion
- 1 Dec 2028 (estimated)
- First posted
- 18 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Glaucoma is a chronic disease that causes loss of vision and potentially blindness as a result of optic nerve damage, often due to increased intraocular pressure. Glaucoma is currently the leading cause of irreversible blindness worldwide.1 In 2020, 4.1 million and 3.6 million adults over the age of 50 suffered from mild to severe glaucoma-induced visual impairment and blindness, respectively.1 However, these figures are likely underestimated since glaucoma can remain asymptomatic until later stages in disease progression.2 The relaxation response evoked by mind-body interventions, such as breathing exercises and meditation, is known to reduce stress and improve quality of life (QOL). In a recent study, mindfulness-based meditation was found to reduce intraocular pressure and improve QOL in patients with glaucoma.3 A feasibility study will be conducted using a mixed-method design to assess the feasibility of the online delivery of meditation for potentially enhancing the QOL and reducing stress in glaucoma patients. Upon recruitment, participants will undergo blocked randomization to either the intervention arm or usual care arm. Participants in each arm will complete online questionnaires at baseline and weeks 1, 3, 6, and 12 to collect data on health-related quality of life (HRQOL), perceived stress, and behaviour using REDCap. REDCap is an online data collection and survey tool hosted by the Office of Research Services of Lawson Research Institute. Our study can help to assess the feasibility of conducting a study on breathing exercises followed by meditation to assess its effects in a sample of patients with glaucoma.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Meditation + Usual Care | Other | Other: Meditation + Usual Care |
| Usual Care | No intervention | – |
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (8 listed)
- Diagnosed with glaucoma or suspected to have glaucoma.
- Aged 65 and above.
- Able to provide valid informed consent to participate in the research study.
- Able to read and understand English.
- No significant self-reported or physician-diagnosed mental health disorder.
Key exclusion criteria (7 listed)
- Inability to provide valid informed consent.
- Significant communication barriers or lack of English proficiency that prevents participants from completing the questionnaires.
- Self-reported substance abuse or dependence within the past 3 months.
- Having acutely unstable medical illnesses, including delirium or acute cerebrovascular or cardiovascular events within the last 6 months.
- Having irreversible vision loss that prevents one from completing the questionnaires.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Meditation + Usual CareMeditation is a guided technique that helps to reduce stress, therefore inducing physiological and mental relaxation whilst the eyes are shut. | Other | Meditation + Usual Care |
Primary outcome
Incidence of Quality of Life as measured by GQOL- 15 in Glaucoma Patients
Time frame: Data will be collected at baseline and post-intervention at Week 1, 3, 6, and 12.
HRQoL will be assessed using Glaucoma Quality of Life-15 (GQL-15). GQL-15 is a disease-specific, validated, self-administered questionnaire designed to measure HRQoL in patients with glaucoma. The questionnaire comprises of 15 items on daily functioning across 5 factors: central and near vision (2 items), peripheral vision (6 items), glare and dark adaptation (6 items), and outdoor mobility (1 item). Patients rate these questions on a 5-point Likert scale of difficulty ranging from "1 = no difficulty" to "5 = severe difficulty".
2 secondary outcomes
Incidence of Stress as Measured by PSS-10 in Glaucoma Patients
Time frame: Data will be collected at baseline and post-intervention at Week 1, 3, 6, and 12.
Incidence of Behavior as measured by Consideration of Future Consequences - 14 (CFC-14) in Glaucoma Patients
Time frame: Data will be collected at baseline and post-intervention at Week 1, 3, 6, and 12.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Aug 2026.
Related trials for Glaucoma
Recruiting
Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers
Glaucoma, Ocular Hypertension
Not yet recruiting
AI-Assisted vs Conventional Teleglaucoma Referral
Glaucoma
Recruiting
Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision Impairment
Retinitis Pigmentosa (RP), Rod Cone Dystrophy
Recruiting
Automated Applanation Tonometry - Updated
Glaucoma, Glaucoma, Suspect
RecruitingPhase 2
A Phase 2a Study Comparing the Efficacy, Safety and Tolerability of Pregabalin Eye Drops Comparing With Timolol Eye Drops in Adults With Glaucoma or High Eye Pressure.
Primary Open - Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
A study of Glaucoma, run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 18 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of Quality of Life as measured by GQOL- 15 in Glaucoma Patients (time frame: Data will be collected at baseline and post-intervention at Week 1, 3, 6, and 12.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Aug 2026.